Centro de Investigación de Medicina Aplicada (CIMA)
Centro / Instituto vinculado a la Universidad de Navarra
University of Parma
Parma, ItaliaPublicaciones en colaboración con investigadores/as de University of Parma (7)
2024
-
AI is a viable alternative to high throughput screening: a 318-target study
Scientific Reports, Vol. 14, Núm. 1
-
Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)
Scientific Reports
-
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma
Nature Communications, Vol. 15, Núm. 1
2022
-
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)
Nature Medicine
-
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
Nature Medicine, Vol. 28, Núm. 3, pp. 557-567
2017
-
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma
Cancer Cell, Vol. 32, Núm. 1, pp. 88-100.e6
2015
-
Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome
Cancer Cell, Vol. 27, Núm. 5, pp. 644-657